BridgeBio Pharma, Inc. Common Stock

BBIONASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
81.38 USD
↗ 1.08 (1.35%)AT CLOSE (11:59 AM EDT)
79.99
↘ 1.39 (1.71%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
79.99
↘ 1.39 (1.71%)
🔴Market: CLOSED

BridgeBio Pharma, Inc. Common Stock (BBIO) trades at $81.39 per share. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (31.7%), a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 17, 2026.

Open?$79.10
High?$82.56
Low?$78.98
Prev. Close?$80.30
Volume?1.4M
Avg. Volume?4.2M
VWAP?$81.47
Rel. Volume?0.34x
Bid / Ask
Bid?$75.66 × 100
Ask?$87.54 × 100
Spread?$11.88
Midpoint?$81.60
Valuation & Ratios
Market Cap?15.7B
Shares Out?195.9M
Float?149.1M
Float %?76.2%
P/E Ratio?N/A
P/B Ratio?-6.90
EPS?-$3.68
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
839
Market Cap
15.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.bridgebio.com
Listed
2019-06-27
Address
3160 PORTER DR.
PALO ALTO, CA 94304
Phone: (650) 391-9740
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
90
Short Sent.?
36
Piotroski F-Score?3/9Weak
Altman Z-Score?-1.95Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?16.16%High
Short Interest?24.1M
Days to Cover?4.5
Free Float149.1M
Avg Daily Volume5.3M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.52Adequate
Quick Ratio?1.48Adequate
Cash Ratio?1.08Strong
Debt/Equity?-1.09Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-6.90CHEAP▾
P/S?
Peers
100
S&P
3
27.12HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-34.7CHEAP▾
EV/Sales?
Peers
100
S&P
3
29.87HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
80
31.7%STRONG▾
ROA?
S&P
3
-52.6%WEAK▾
Cash Flow & Enterprise
FCF?$-445120000
Enterprise Value?$17.3B
Fundamentals ratios updated end of day
MarketsMoversWatchlist